NEW YORK (GenomeWeb News) – Sequenom today said that it has inked a contract with sales and marketing services firm PDI to provide the sales force that will launch and commercialize the firm's SEQureDx non-invasive prenatal genetic screening tests.

PDI will work with the Sequenom Center for Molecular Medicine, the clinical lab subsidiary of Sequenom, in supporting commercialization of the firm's Rhesus D genotyping test, its Down syndrome test, and other laboratory-developed tests. The partners will hire, train, and develop a sales team for the SCMM.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.